All In Biotech

Drug Trial Radar · NCT04758962

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Feb 15, 2021

Primary completion

Jun 4, 2021

Study completion Apr 19, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike antigen (CoV-2 SAM \[LNP\] vaccine) in ascending doses when administered intramuscularly (IM) on a 0,1-month schedule to healthy adults 18 to 50 years of age. There will be no administration of escalated doses of the study vaccine.

Conditions

  • Virus Diseases

Interventions

  • 1 µg CoV2 SAM (LNP)Biological

    2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Administration Site Adverse Events After Each VaccinationTime frame: Within 7 days post each vaccination (vaccination at Day 1 and Day 31)
  2. Number of Participants With Solicited Systemic Adverse Events After Each VaccinationTime frame: Within 7 days post each vaccination (vaccination at Day 1 and Day 31)
  3. Number of Participants With Unsolicited Adverse Events (AEs) After Each VaccinationTime frame: Within 30 days post each vaccination (vaccination at Day 1 and Day 31)
  4. Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 2 Compared With Baseline (Day 1)Time frame: Day 2 compared to baseline (Day 1)
  5. Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 8 Compared With Baseline (Day 1)Time frame: Day 8 compared to baseline (Day 1)
  6. Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 31 Compared With Baseline (Day 1)Time frame: Day 31 compared to baseline (Day 1)
  7. Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 32 Compared With Baseline (Day 1)Time frame: Day 32 compared to baseline (Day 1)
  8. Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 38 Compared With Baseline (Day 1)Time frame: Day 38 compared to baseline (Day 1)
  9. Number of Participants With Medically-attended AEs (MAEs) From Day 1 to Day 61Time frame: Day 1 to Day 61
  10. Number of Participants With Serious AEs (SAEs) From Day 1 to Day 61Time frame: Day 1 to Day 61
  11. Number of Participants With Adverse Events of Special Interest (AESIs) [Potential Immune-mediated Diseases (pIMDs) and COVID-19 Cases) From Day 1 to Day 61Time frame: Day 1 to Day 61

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.